Infection Risk Lower for Etanercept Vs Monoclonal Ab Rx

Share this content:
Infection Risk Lower for Etanercept Vs Monoclonal Ab Rx
Infection Risk Lower for Etanercept Vs Monoclonal Ab Rx

THURSDAY, Feb. 9, 2017 (HealthDay News) -- For patients with rheumatoid arthritis, etanercept is associated with lower risk for general infections and tuberculosis compared with monoclonal antibody treatment, according to a meta-analysis published online Feb. 3 in the International Journal of Rheumatic Diseases.

Hongxing Liao, from the Meizhou People's Hospital in China, and colleagues conducted a systematic literature review to examine the differences between monoclonal antibodies and the soluble receptor for infections in patients with RA. Twelve studies were included that reported infections in patients with RA treated with the soluble receptor etanercept or at least one monoclonal antibody (infliximab or adalimumab).

The researchers found that the soluble receptor was associated with a lower incidence rate of serious infection compared with monoclonal antibodies (relative risk, 0.63), although there was high heterogeneity (I² = 85 percent) and the possibility of publication bias. The pooled analysis showed that the soluble receptor was associated with lower risk of tuberculosis (relative risk, 0.19), with low heterogeneity (I² = 0 percent) and no publication bias. Etanercept was associated with lower risk than mono-antibodies for general infections (relative risk, 0.66) with high heterogeneity (I² = 79 percent).

"More well-designed long-term prospective studies would be important to strengthen these findings," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »